Edward Neuwelt
Portland, ORNPI 1114022837
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,449 of the $3,699 with a category attached, or 93.3%. AMAG Pharmaceuticals, Inc. accounts for 96.9% of it on its own, with 1 other manufacturer making up the rest.
Across 4 payments — averaging $924.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AMAG Pharmaceuticals, Inc.$4K
- Merck$115
Across 33 payments — averaging $149,671 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$4.3M
- AMAG Pharmaceuticals, Inc.$440K
- Bristol Myers Squibb$180K
- Genentech, Inc.$57K
What the payments were for
- Consulting fees$3,44993%
- Food & beverage$2507%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AMAG Pharmaceuticals, Inc. | 3 | $3,584 |
| Merck | 1 | $115 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FERAHEME$3,584
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.